Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a brand-name drug prescribed for certain cancers. Enhertu comes as an intravenous (IV) infusion given by a healthcare professional. The dosage can vary ...

Capital structure is the mix of debt and equity that fund a company's operations. A judicious use of debt and equity is a key indicator of a strong balance sheet. A healthy capital structure that ...

Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the ...

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).